Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02486406 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
A Phase 2 study of Chronic Hepatitis C Infection, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 20
- Study locations
NCT02486406 is a Phase 2 study of Chronic Hepatitis C Infection that has completed, run by AbbVie. The registered enrollment target is 64 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT02486406, a Phase 2 study of Chronic Hepatitis C Infection, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV) in Hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4)-infected pediatric participants of ≥ 3 to 17 years of age.
Conditions Studied
Interventions
- DRUG Ribavirin
- DRUG Ombitasvir/paritaprevir/ritonavir
- DRUG Dasabuvir
- DRUG Ombitasvir mini tablet
- DRUG Paritaprevir mini tablet
Study Locations (20)
Other
- UZ Leuven /ID# 136911 - Leuven
- Charite Universitaetsmedizin Berlin /ID# 141620 - Berlin
- Universitaetsklinikum Freiburg /ID# 141618 - Freiburg im Breisgau
- Helios Klinikum Wuppertal /ID# 142883 - Wuppertal
- San Jorge Children Hospital /ID# 136832 - San Juan
- Hospital Universitario Vall d'Hebron /ID# 137098 - Barcelona
- Hospital Universitario La Paz /ID# 137094 - Madrid
Florida
- University of Florida - Archer /ID# 136830 - Gainesville
- Advent Health /ID# 167663 - Orlando
Massachusetts
- Boston Childrens Hospital /ID# 137174 - Boston
- Boston Medical Center /ID# 136831 - Boston
California
- UCSF Benioff Childrens Hosp /ID# 136774 - San Francisco
Colorado
- Children's Hospital Colorado /ID# 137017 - Aurora
Indiana
- Indiana University /ID# 137015 - Indianapolis
New York
- Columbia Univ Medical Center /ID# 136431 - New York
Pennsylvania
- Children's Hospital of Philadelphia /ID# 137018 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-10-28 |
| Est. Completion | 2020-11-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02486406
The ClinicalTrials.gov registry entry for NCT02486406 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis C Infection appearing as the primary indexed condition, and to 5 interventions - of which Ribavirin is the first listed.
NCT02486406 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02486406 about?
NCT02486406 is a clinical study titled "A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects". This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV) in Hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4)-infected pedi...
What is the current status of trial NCT02486406?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2015-10-28. Estimated completion is 2020-11-19.
What conditions does trial NCT02486406 study?
This clinical trial studies the following conditions: Chronic Hepatitis C Infection.
What interventions are being tested in trial NCT02486406?
The interventions under investigation include: Ribavirin (DRUG), Ombitasvir/paritaprevir/ritonavir (DRUG), Dasabuvir (DRUG), Ombitasvir mini tablet (DRUG), Paritaprevir mini tablet (DRUG).
Who is sponsoring clinical trial NCT02486406?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02486406 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.